Literature DB >> 7738167

Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.

M Riegler1, R Sedivy, C Pothoulakis, G Hamilton, J Zacherl, G Bischof, E Cosentini, W Feil, R Schiessel, J T LaMont.   

Abstract

Toxin A but not toxin B, appears to mediate intestinal damage in animal models of Clostridium difficile enteritis. The purpose of this study was to investigate the electrophysiologic and morphologic effects of purified C. difficile toxins A and B on human colonic mucosa in Ussing chambers. Luminal exposure of tissues to 16-65 nM of toxin A and 0.2-29 nM of toxin B for 5 h caused dose-dependent epithelial damage. Potential difference, short-circuit current and resistance decreased by 76, 58, and 46%, respectively, with 32 nM of toxin A and by 76, 55, and 47%, respectively, with 3 nM of toxin B, when compared with baseline (P < 0.05). 3 nM of toxin A did not cause electrophysiologic changes. Permeability to [3H]mannitol increased 16-fold after exposure to 32 nM of toxin A and to 3 nM of toxin B when compared with controls (P < 0.05). Light and scanning electron microscopy after exposure to either toxin revealed patchy damage and exfoliation of superficial epithelial cells, while crypt epithelium remained intact. Fluorescent microscopy of phalloidin-stained sections showed that both toxins caused disruption and condensation of cellular F-actin. Our results demonstrate that the human colon is approximately 10 times more sensitive to the damaging effects of toxin B than toxin A, suggesting that toxin B may be more important than toxin A in the pathogenesis of C. difficile colitis in man.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738167      PMCID: PMC295778          DOI: 10.1172/JCI117885

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts.

Authors:  N Wedel; P Toselli; C Pothoulakis; B Faris; P Oliver; C Franzblau; T LaMont
Journal:  Exp Cell Res       Date:  1983-10-15       Impact factor: 3.905

2.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  Differential effects of Clostridium difficile toxins on tissue-cultured cells.

Authors:  S T Donta; N Sullivan; T D Wilkins
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

5.  Biochemical and pathological effects of Clostridium difficile toxins in mice.

Authors:  M Ehrich
Journal:  Toxicon       Date:  1982       Impact factor: 3.033

6.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters.

Authors:  J G Bartlett; A B Onderdonk; R L Cisneros; D L Kasper
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

7.  Clostridium difficile toxin B disrupts the barrier function of T84 monolayers.

Authors:  G Hecht; A Koutsouris; C Pothoulakis; J T LaMont; J L Madara
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

8.  Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; N Moon; T W Chang; N Taylor; A B Onderdonk
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

9.  Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis.

Authors:  G D Abrams; M Allo; G D Rifkin; R Fekety; J Silva
Journal:  Gut       Date:  1980-06       Impact factor: 23.059

10.  Effects of Clostridium difficile toxins given intragastrically to animals.

Authors:  D M Lyerly; K E Saum; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

View more
  108 in total

1.  p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis.

Authors:  M Warny; A C Keates; S Keates; I Castagliuolo; J K Zacks; S Aboudola; A Qamar; C Pothoulakis; J T LaMont; C P Kelly
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Cytoskeletal effects induced by pet, the serine protease enterotoxin of enteroaggregative Escherichia coli.

Authors:  F Navarro-García; C Sears; C Eslava; A Cravioto; J P Nataro
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

4.  The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B.

Authors:  M H Souza; A A Melo-Filho; M F Rocha; D M Lyerly; F Q Cunha; A A Lima; R A Ribeiro
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

5.  Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.

Authors:  Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 6.  Recognition and prevention of hospital-associated enteric infections in the intensive care unit.

Authors:  Linda D Bobo; Erik R Dubberke
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

7.  Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

Authors:  C Pothoulakis; R J Gilbert; C Cladaras; I Castagliuolo; G Semenza; Y Hitti; J S Montcrief; J Linevsky; C P Kelly; S Nikulasson; H P Desai; T D Wilkins; J T LaMont
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 8.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

9.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

10.  Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock.

Authors:  T Sautner; C Wessely; M Riegler; R Sedivy; P Götzinger; U Losert; E Roth; R Jakesz; R Függer
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.